Opinion|Videos|July 11, 2024
Exploring Results from CAPItello-291 Trial
William J. Gradishar, MD, examines the impact of the CAPItello-291 phase III trial on NCCN breast cancer guidelines, comparing the investigated drug to other PI3K pathway inhibitors and discussing its potential to shape future treatment strategies.
Advertisement
Episodes in this series
- In November 2023, capivasertib received FDA approval for use in advanced hormone receptor-positive breast cancer based on the results from the
CAPItello-291 phase III trial. How has capivasertib been integrated into the NCCN guidelines for breast cancer?
- What are your thoughts on sequencing of capivasertib use in the management of HR+ breast cancer?
- How does capivasertib compare to other PI3K pathway inhibitors alpelisib and inavolisib from safety and efficacy standpoints?
Advertisement
Related to this article
Non-CF bronchiectasis prevalence rose across commercial, Medicare, and Medicaid plans from 2016 to 2024, while incidence stayed relatively stable.
Shorter telomere length was linked to a usual interstitial pneumonia pattern (UIP) on CT in patients with ILD, per research presented at CHEST 2026.
Low awareness that fatty liver can silently progress and that MASH fibrosis is treatable drives missed follow-up testing, says Rohit Loomba, MD.
The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.
The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer.
Advertisement
Advertisement
Trending on AJMC
1
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
2
Early-Onset Cancers Often Found Late as Screening Gaps Persist
3
Study Finds Possible Deep Endometriosis in 7% of Postmenopausal Women
4
AHIP's Jeanette Thornton on Prior Authorization Reform, Midterms
5